Emre Tepeli

Emre Tepeli

Auto-generated profile, based on publicly available information

Emre Tepeli

Department of Genetics, Istanbul Atlas University Faculty of Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
BHBülent Hacıhamdioğlu
Bülent Hacıhamdioğlu
GÖGamze Özgürhan
Gamze Özgürhan
CPCatarina Pereira
Catarina Pereira
ETEmre Tepeli
Emre Tepeli
GAGülşen Acar
Gülşen Acar
SCSerdar Comert
Serdar Comert
Hypophosphatasia (HPP) is a rare disease caused by mutations in the ALPL gene encoding tissue-non-specific isoenzyme of alkaline phosphatase (TNSALP). Duplications of the ALPL gene account for fewer than 1 % of the mutations causing HPP. It has been shown that asfotase alfa enzyme replacement treatment (ERT) mineralizes the skeleton and improves respiratory function and survival in severe forms of HPP. Our patient was a newborn infant evaluated for respiratory failure and generalized hypotonia after birth. Diagnosis of HPP was based on low-serum ALP activity, high concentrations of substrates of the TNSALP and radiologic findings. On day 21 after birth, ERT using asfotase alfa (2 mg/kg three times per week, subcutaneous injection) was started. His respiratory support was gradually reduced and skeletal mineralization improved during treatment. We were able to discharge the patient when he was seven months old. No mutation was detected in the ALPL gene by all exon sequencing, and additional analysis was done by quantitative polymerase chain reaction (qPCR). As a result, a novel homozygote duplication encompassing exons 2 to 6 was detected. Early diagnosis and rapid intervention with ERT is life-saving in the severe form of HPP. qPCR can detect duplications if a mutation cannot be detected by sequence analysis in these patients.

27 August 2022 in European Journal of Inflammation
Verified
Journal Article
Open access
ÜÖÜmit Özkan
Ümit Özkan
FUFirdevs Ulutaş
Firdevs Ulutaş
ETEmre Tepeli
Emre Tepeli
VÇVeli Çobankara
Veli Çobankara
Objective: The objective of this study was to investigate whether interleukin-1 (IL-1) gene polymorphisms are associated with susceptibility to Behçet’s disease (BD) and clinical manifestations of the disease. Methods: In this cross-sectional study, we enrolled 110 patients with BD and age-and gender-matched 120 healthy controls. Five polymorphic regions of the IL-1 gene including rs 1800587 (IL1A-889 C/T), rs 2234650 (IL1R1), rs 16944 (IL1B-511 C/T), rs 315952 (IL1RN), and rs1143634 (IL1B-3954 C/T) were analyzed by using the real-time polymerase chain reaction system. Allele frequencies and genotypes were compared between groups. p ≤ 0.05 was accepted as statistically significant. Results: The mean age of the patients with BD was 41 ± 12.4 years. The two groups were similar in terms of the age and gender distribution. The vast majority of BD patients had mucocutaneous involvement. The mean disease duration was 83.7 ± 67.8 months among the patients. The frequencies of each polymorphism in the IL-1 gene were similar between patients with BD and healthy controls. Conclusion: The frequencies of variable IL-1 gene polymorphisms were similar between patients with BD and healthy controls.

1 June 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
STSahin Temel
Sahin Temel
ABA. Balkarli
A. Balkarli
ETE. Tepeli
E. Tepeli
VCV. Cobankara
V. Cobankara
Background There are many studies about the association between AS and IL-23 receptor gene polymorphism. It is known that the frequency of SS increase in AS patients. There is not any study that evaluates the association between patients that have both AS and SS and IL-23R gene polymorphism. Objectives We studied the possible association of IL-23 receptor gene polymorphisms in patients with Primary Sjögren syndrome, Ankylosing spondylitis, and Ankylosing spondylitis with Sjogren's syndrome. Methods 124 AS, 55 SS, 12 both AS and SS and 96 healthy controls recruited for this study. IL-23 gene, rs11805303, rs10889677, rs1004819, rs2201841, rs11209032, rs7530511, rs11209026, rs10489629, rs7517847 variants were studied by PCR-RFLP method. Results rs10889677 gene mutant genotype frequency was statistically higher and rs11209032 gene mutant genotype frequency was statistically less in A.S. group compared with healthy controls (p=0,023, p<0,001). Both of rs2201841 and rs11805303 gene wild genotype frequency was statistically higher in SjS group compared with healthy controls (p<0,001, 0,009), rs11209032 gene heterozygous and rs10489629 gene mutant genotype frequency was statistically less in SS group compared with healthy controls (p<0,001, 0,003). In the group of patients with AS and SS rs11209032 gene wild genotype frequencies were significantly increased compared to the control group (p<0,001). rs11805303 and rs10489629 gene mutant genotype frequencies were significantly increased in AS group compared to the SS group, but in the group of patients with SS; rs10889677 gene heterozygous, rs2201841 gene wild and rs11209032 gene mutant genotype frequencies were significantly increased compared to the AS group. In the group of patients with AS and SS rs11209032 gene wild genotype frequencies were significantly increased compared to the AS group (p=0,049). In the group of patients with AS and SS; rs11805303 gene mutant, rs11209032 gene wild, rs10489629 gen mutant genotype frequencies were significantly increased compared to the SS group (p<0,05). Although rs10889677 gene mutant genotype can be interpreted as predisposition of AS, rs11209032 gene mutant genotype can be protective from AS. There is only one study about IL-23 gene polymorphism in SS patients in literature and no relationship was found. In the group of patients with SS; rs11805303 gene wild genotype and rs2201841 gene wild genotype frequencies were significantly increased, but rs11209032 gene heterozygous genotype and rs10489629 gene mutant genotype decreased compared to the control group. Conclusions According to our results we have found both rs11805303 gene wild genotype and rs2201841 gene wild genotype can predispose to SS and rs11209032 gene heterozygous genotype and rs10489629 gene mutant genotype protect from SS. rs11209032 gene mutant and heterozygous genotype frequencies which interpreted as protective from AS and SS were significantly decreased in the group of AS and SS patients compared to the AS group, but wild gentoype frequencies were increased. These results of rs11209032 genotype wild gene may be associated with the development of SS in patients with AS. Genotype distribution and genetic diversity varies between ethnic groups. Disclosure of Interest None declared

2 May 2025
Verified
Book
Open access
PDF file
ABAyhan Bilir
Ayhan Bilir
AKAhmet Kalaycıoğlu
Ahmet Kalaycıoğlu
NBNureda Nalçacı Bozkurt
Nureda Nalçacı Bozkurt
AMAli Osman Muçuoğlu
Ali Osman Muçuoğlu
NANiyazi Acer
Niyazi Acer
HDHüseyin Doğu
Hüseyin Doğu
Chiari Malformasyonu Tarihçesi, Sınıflandırmaları Hidayet AKDEMİR Chiari Malformasyonları Bağlantılı Doku ve Organların Embriyonal Gelişim Süreçleri Ayhan BİLİR Posterior Fossa ve Kraniyovertebral Anatomi Ahmet KALAYCIOĞLU Nureda NALÇACI BOZKURT Chiari Malformasyonlarında Klinik Semptom ve Bulgular, Ayırıcı Tanı ve Klinik Testler Ali Osman MUÇUOĞLU Chiari Malformasyonlarının Radyolojik Tarihçesi ve Güncel Volumetrik Yaklaşımlar Niyazi ACER Mustafa TAŞTAN Chiari Malformasyonları Elektrofizyoloji Demet AYGÜN ÜSTEL Ailesel Chiari Malformasyonu Oya AKÇA Hilal ŞAHİN Emre TEPELİ Pediatrik Chiari Malformasyonları Nazlı ÇAKICI ÖKSÜZ Chiari Malformasyonunda Epidemiyoloji, Konservatif Tedaviler ve Gebelikte Hasta Yönetimi Meltem CAN İKE Chiari Malformasyonları Cerrahi Tedavisinin Tarihçesi ve Güncel Yaklaşımlar Hidayet AKDEMİR Chiari Tip I Malformasyonunda Dural Dış Tabakanın Alınması ile Dekompresyon Rahmi Kemal KOÇ Halil ULUTABANCA Chiari Malformasyonları ve Baziller İnvaginasyon Ebubekir AKPINAR İlhan YILMAZ Chiari Malformasyonu ve Siringomiyeli Hidayet AKDEMİR Chiari Malformasyonu Cerrahisinin Komplikasyonları Hüseyin DOĞU Chiari Malformasyonu: Aile Rehberi Hidayet AKDEMİR

1 November 2025 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
HDHüseyin Doğu
Hüseyin Doğu
AMAli Osman Mucuoglu
Ali Osman Mucuoglu
AGAbdulkerim GÖKOĞLU
Abdulkerim GÖKOĞLU
RGRoya Gasimli
Roya Gasimli
ETEmre Tepeli
Emre Tepeli
HAHidayet Akdemir
Hidayet Akdemir
Objective : Familial cerebral cavernous malformation (FCCM) is a genetically inherited condition involving the collection of abnormal slow-flow venous capillaries with no cerebral parenchyma in between. In this case series, we review the clinical, radiological, pathological, and genetic findings of seven blood relatives diagnosed with FCCM and discuss their treatment in light of the different presentations.Methods : The patients with FCCMs were assessed in our neurosurgery clinic between April 2016 and October 2024. All patients underwent detailed clinical evaluation, radiological imaging, histopathological examination, and genetic testing. Functional outcomes were evaluated using the Karnofsky performance scale (KPS).Results : Five of the seven patients were symptomatic, while the remaining two were asymptomatic carriers. On radiological examination, hemorrhagic type I lesions were detected in symptomatic cases, whereas the asymptomatic carriers had non-hemorrhagic type 4 lesions. Genetic testing revealed a heterozygous pathogenic mutation in the CCM1 gene in one of the symptomatic patients. The three symptomatic cases underwent surgery for complete resection of the lesions; no additional neurological deficit or residual lesion was detected postoperatively (postoperative KPS score, 100). Histopathological examination revealed benign cavernous angioma in all cases. Over the postoperative follow-up, no seizures were detected in patients who underwent surgery due to refractory epilepsy.Conclusion : Advances in molecular genetic testing have allowed for prompt diagnosis and timely management of patients with FCCMs. Surgical treatment is an effective option in symptomatic cases with progressive neurological deficits and refractory epilepsy. Regular neurological monitoring and radiological assessment are recommended in symptomatic cases and asymptomatic carriers.

2 May 2025
Verified
Book Chapter
Closed access
OAOya Akça
Oya Akça
HŞHilal Şahin
Hilal Şahin
ETEmre Tepeli
Emre Tepeli
Bu bölüm, beyin dokusunun spinal kanala uzandığı serebellumun konjenital yapısal bir anomalisi olan Chiari Malformasyonu'nun (CM) kalıtımla ilgili yönlerini araştırmaktadır. CM'nin, özellikle de yetişkinlerde en sık görülen Chiari Malformasyonu Tip I (CM-I) altında yatan genetik temel, kalıtım modelleri ve moleküler mekanizmalar tartışılmaktadır. Bu bölümde ayrıca genetik sınıflandırma, tanı yöntemleri ve tüm-ekzom dizileme (WES), genom çapında ilişkilendirme çalışmaları (GWAS) ve karşılaştırmalı genomik hibridizasyon (CGH) gibi moleküler teknikler de ele alınmaktadır. CM'yi etkileyen genetik ve çevresel faktörlerin anlaşılması, erken tanı ve hedefe yönelik tedavi stratejilerini geliştirebilir. This chapter explores the inheritance related aspects of Chiari Malformation (CM), a congenital structural anomaly of the cerebellum where brain tissue extends into the spinal canal. It discusses the genetic basis, inheritance patterns, and molecular mechanisms underlying CM, particularly Chiari Malformation Type I (CM-I), the most common form in adults. The chapter also covers genetic classification, diagnostic methods, and molecular techniques such as whole-exome sequencing (WES), genome-wide association studies (GWAS), and comparative genomic hybridization (CGH). Understanding the genetic and environmental factors influencing CM can enhance early diagnosis and targeted treatment strategies.